Table 1. Clinical characteristics of the 40 participants in cohort 1.
| Group | Age | Sex | ISS | ALB (g/L) | IL-6 (pg/mL) | LDH (U/L) | β2-MG (ng/mL) | GLB (g/L) | SCR (µmol/L) |
|---|---|---|---|---|---|---|---|---|---|
| Normal control (NC, n = 20) | 55.10 ± 10.43 | Female (n = 8) Male (n = 12) |
– | 42.16 ± 6.12 | 4.21 ± 1.98 | 183.00 ± 66.28 | 1037.05 ± 423.28 | 27.62 ± 6.51 | 67.88 ± 33.47 |
| Multiple myeloma (MM, n = 20) | 54.90 ± 11.29 | Female (n = 8) Male (n = 12) |
ISS I (n = 4) 1SS II (n = 6) ISS III (n = 10) |
37.89 ± 9.08 | 12.24 ± 14.72a∗ | 241.20 ± 112.80 | 10,846.45 ± 10,615.85aΔ | 49.56 ± 26.42aΔ | 243.75 ± 229.60a# |
Notes.
Abbreviations
- ISS
- International Staging System
- ALB
- albumin, reference range: 40–55
- IL-6
- interleukin 6, reference range: 0.00–5.30
- LDH
- lactic dehydrogenase, reference range: 120–250
- β2-MG
- β2-microglobulin, reference range: 609–2366
- GLB
- globulin, reference range: 20–40
- SCR
- serum creatinine, reference range: 41.0–73.0
a
Compared with the NC group, ∗Significant association with P < 0.05, #Significant association with P < 0.01, ΔSignificant association with P < 0.001.